Nephrogenic systemic fibrosis (NSF) is a rare, potentially disabling disorder characterized by excessive fibrosis in the skin and, in some cases, deeper tissues and internal organs. It occurs predominantly in people with severe impairment of kidney function and is strongly associated with exposure to certain gadolinium-based contrast agents used in magnetic resonance imaging (MRI). Skin thickening, limb stiffness, and joint contractures are characteristic features. The risk differs substantially among contrast agents, and new cases have become uncommon following changes in their selection and use.
Recognition and terminology
The condition was initially recognized in patients with advanced kidney disease and described in the medical literature in 2000 as nephrogenic fibrosing dermopathy. This name emphasized its skin manifestations. Subsequent recognition of involvement beyond the skin led to the term nephrogenic systemic fibrosis.
The association with gadolinium-based contrast exposure was identified in 2006. It prompted regulatory warnings, screening of kidney function in relevant settings, and restrictions on agents most strongly implicated in the disorder.
Risk factors and contrast-agent differences
The principal setting for NSF is markedly reduced renal clearance, particularly in people with acute kidney injury, advanced chronic kidney disease, or kidney failure requiring dialysis. In chronic kidney disease, historical cases were concentrated among patients with an estimated glomerular filtration rate below . Estimates based on blood creatinine are less reliable when kidney function is changing rapidly.
Most well-documented cases followed exposure to older, less stable linear gadolinium agents, including gadodiamide, gadopentetate dimeglumine, and gadoversetamide. Higher doses and repeated administrations were additional features of many historical cases.
Risk is not uniform across all gadolinium agents:
- Linear and macrocyclic structure: Macrocyclic agents bind gadolinium within a ring-like molecular structure and generally have greater kinetic stability than linear agents. Molecular structure is relevant but does not, by itself, fully define clinical risk.
- Clinical risk categories: Professional guidelines classify agents according to their observed association with NSF. Agents in the American College of Radiology’s Group II have few, if any, unconfounded NSF cases associated with their use.
- Modern exposure: Evidence indicates that the NSF risk from Group II agents at standard diagnostic doses is extremely low, including in people with advanced kidney disease. This differs sharply from the historical risk associated with higher-risk agents.
NSF is not a general consequence of MRI: MRI does not always require a contrast agent, and the disorder is associated with particular contrast exposures in susceptible patients rather than with the magnetic field.
Proposed biological mechanism
Gadolinium is administered in a chelated form, in which it is bound to an organic molecule. Severe kidney impairment can prolong the time that many gadolinium agents remain in the body. With less stable agents, this may increase the opportunity for gadolinium to dissociate from its chelate and become deposited in tissues.
The precise sequence leading to NSF remains incompletely understood. Proposed mechanisms involve tissue injury, inflammatory signaling, recruitment of circulating fibrocytes, and activation of cells that produce collagen and other extracellular-matrix components. Gadolinium has been detected in affected tissues, but deposition alone does not explain why only a small proportion of exposed patients develop NSF.
Gadolinium retention and NSF are therefore distinct concepts. Detectable retention can occur without the characteristic clinical and tissue changes of NSF and does not itself establish the diagnosis.
Clinical features
Symptoms often begin within weeks to months of the implicated exposure, although longer intervals have been reported. Early findings may include swelling, redness, itching, burning, and pain, followed by progressive skin thickening and hardening.
Typical manifestations include:
- Symmetrical involvement of the limbs, often with relative sparing of the face.
- Firm plaques or skin with a woody, tethered, or orange-peel texture.
- Reduced joint mobility and fixed contractures.
- Difficulty walking or performing everyday activities.
Fibrosis can extend into fascia and muscle. Internal involvement, including the diaphragm, lungs, and heart, has been documented in severe cases. The course ranges from limited or relatively stable disease to progressive disability. Serious functional impairment may persist even after the initiating exposure has ceased.
Diagnosis
Diagnosis combines the clinical pattern, kidney-function history, contrast-exposure history, and findings from a sufficiently deep skin biopsy. No single blood test establishes NSF.
Characteristic Histopathological findings include thickened collagen bundles, increased spindle-shaped fibrocytic cells, and variable mucin deposition, sometimes extending into the subcutaneous tissue. CD34-positive spindle cells can support the diagnosis, but their presence is not independently diagnostic.
The differential diagnosis includes systemic sclerosis, scleromyxedema, eosinophilic fasciitis, and other causes of skin induration or joint restriction. Clinical and pathological findings must be interpreted together because individual features can overlap with these disorders.
Management and outcomes
No treatment has consistently reversed NSF in controlled studies. Published treatment evidence consists largely of case reports and small series, making effectiveness difficult to establish.
Management has included treatment of the underlying kidney disorder, measures to preserve mobility, and symptom control. Improvement has sometimes followed recovery of kidney function or kidney transplantation, but established fibrosis and contractures may persist. Physical therapy and rehabilitation address functional limitations rather than directly removing tissue fibrosis. Various drug treatments and photopheresis have been reported, without establishing a universally effective disease-modifying therapy.
Hemodialysis removes circulating gadolinium contrast, but removal after exposure has not been shown to reliably prevent NSF.
Prevention and changing epidemiology
The marked decline in new cases followed avoidance of higher-risk agents in susceptible patients, improved recognition of severe renal impairment, and broader use of lower-risk alternatives. Contemporary radiology guidance differentiates contrast agents rather than treating them as having equivalent NSF risk.
The historical incidence associated with older agents cannot be directly applied to current practice. Present-day assessments distinguish the specific agent, dose, kidney-function status, and clinical context; the very low risk associated with modern lower-risk agents is not equivalent to proof of zero risk.